Anticoagulation Timing in Atrial Flutter and Ischemic Stroke

Introduction to Anticoagulation Timing

The American Heart Association recommends delaying oral anticoagulation for 10-14 days after an acute ischemic stroke event to minimize the risk of hemorrhagic transformation in patients with large infarcts, such as those with an NIHSS score of 19 1
A large infarct, defined by an NIHSS score >15 or involving complete arterial territory, significantly increases the risk of hemorrhagic transformation with early anticoagulation, and it is reasonable to delay oral anticoagulation for 14 days after the onset of stroke in such cases 1

The American College of Cardiology suggests that anticoagulation should not be initiated with heparinoids or warfarina within the first 48 hours of an acute ischemic stroke, as it increases the risk of symptomatic intracranial hemorrhage without providing net benefit 2
Early parenteral anticoagulation increases the risk of symptomatic intracranial hemorrhage without providing net benefit, and heparinoids as bridging therapy in the acute phase are contraindicated 2, 3

For large infarcts (NIHSS >15), a suggested algorithm is: no anticoagulation for the first 2 days, continuation of no anticoagulation from days 3-13 to allow stabilization of the blood-brain barrier, neuroimaging on day 14 to evaluate for hemorrhagic transformation, and initiation of oral anticoagulation after day 14 if neuroimaging is stable without significant hemorrhage 1, 2

The American College of Cardiology recommends preferring direct oral anticoagulants (DOACs) over warfarina for patients with atrial flutter, similar to those with atrial fibrillation, due to their reduced risk of stroke or systemic embolism and lower risk of hemorrhagic stroke 1, 4, 5, 6, 7
DOACs, such as apixaban, dabigatran, rivaroxaban, or edoxaban, are preferred as first-line treatment, showing a 19% reduction in stroke or systemic embolism compared to warfarina, with 51% less hemorrhagic stroke 1

Advanced age does not contraindicate anticoagulation; in fact, it increases the risk of recurrent stroke, and for patients over 75 years with increased bleeding risk but no absolute contraindications, some experts suggest a lower INR target (1.6-2.5) if warfarin is used, although DOACs are preferred 4, 5, 6, 7

Atrial flutter is managed with the same antithrombotic strategy as atrial fibrillation, with a clear indication for long-term anticoagulation given the patient's previous stroke 4, 6

Before initiating anticoagulation, evaluate the HAS-BLED score, which includes hypertension, abnormal renal/liver function, previous stroke, history of bleeding, labile INR, age >65, and drugs/alcohol, and a score ≥3 indicates high risk, requiring caution and regular follow-up, but does not contraindicate anticoagulation 8

Avoid using "bridging therapy" with heparin, as it increases risk without benefit, and do not initiate anticoagulation too early (<48 hours), as it increases the risk of hemorrhagic expansion 2, 3
Do not underestimate the size of the infarct, as an NIHSS score of 19 indicates a large infarct requiring a 14-day wait before initiating anticoagulation, and do not omit follow-up neuroimaging, which is essential before starting anticoagulation 1, 3

Monitor for signs of recurrent bleeding after initiating anticoagulation, ensure optimal blood pressure control to minimize the risk of recurrent hemorrhage, and if using warfarin, monitor INR weekly during initiation and monthly when stable 3, 6, 7
If using DOACs, evaluate renal function at least annually 6

Oral anticoagulation should be continued indefinitely for secondary prevention, and this patient has a Class I indication for anticoagulation given her previous stroke and atrial flutter 2, 6, 7